Sugi Predict

Sugi Predict / Compounds / SCHEMBL371850

SCHEMBL371850

SCHEMBL371850

COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ncnc2cc1OCC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 16/20 0.70
▸ KDR P35968 8/20 0.58
▸ AXL P30530 5/20 0.56
▸ RET P07949 3/20 0.52
▸ KIT P10721 3/20 0.52
▸ FLT3 P36888 3/20 0.52
▸ PDGFRB P09619 2/20 0.52
▸ EGFR P00533 2/20 0.52
▸ MERTK Q12866 2/20 0.52
▸ RAF1 P04049 2/20 0.52
▸ PLK4 O00444 1/20 0.52
▸ STK25 O00506 1/20 0.52
▸ CIT O14578 1/20 0.52
▸ AURKA O14965 1/20 0.52
▸ CHUK O15111 1/20 0.52
▸ MUSK O15146 1/20 0.52
▸ EPHB6 O15197 1/20 0.52
▸ MAPK13 O15264 1/20 0.52
▸ MAP3K13 O43283 1/20 0.52
▸ DAPK3 O43293 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15918385 0.91 MET (0.70) METKDRAXLRETKIT
SCHEMBL29693455 0.90 MET (0.77) METKDRAXLRETKIT
SCHEMBL371930 0.90 MET (0.77) METKDRAXLRETKIT
SCHEMBL371975 0.90 MET (0.77) METKDRAXLRETKIT
SCHEMBL29693496 0.90 MET (0.77) METKDRAXLRETKIT
SCHEMBL19689583 0.89 MET (0.54) METKDRAXLRETKIT
SCHEMBL10452721 0.87 MET (0.52) METKDRAXLRETKIT
SCHEMBL4401204 0.86 MET (0.78) METKDRAXLRETKIT
SCHEMBL19373119 0.85 MET (0.69) METKDRAXLRETKIT
SCHEMBL371651 0.84 MET (1.00) METKDRAXLRETKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
EP-1673085-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-06-28 — — EP disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KDR 4/4885AXL 109/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MET 3/4885KDR 4/4885AXL 109/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KDR 4/4885AXL 109/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MET 3/4885KDR 4/4885AXL 109/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885KDR 5/4885AXL 241/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885KDR 5/4885AXL 241/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MET 3/4885KDR 4/4885AXL 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.